Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Cash from Financing Activities of -$11.6 million for Q1 2026, up 36.2% year-over-year from -$8.5 million in Q1 2025, and up 88.47% quarter-over-quarter from -$100.8 million in Q4 2025.
Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Cash from Financing Activities for 13 consecutive years, with -$11.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 36.2% year-over-year to -$11.6 million; the TTM figure through Mar 2026 stood at -$310.0 million (down 158.52% YoY), while the FY2025 annual figure was -$316.6 million, down 167.08% from the prior year.
- Cash from Financing Activities rose to -$11.6 million in Q1 2026 per LNTH's latest filing, from -$100.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $317.8 million in Q4 2022 and bottomed at -$103.7 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$8.7 million across 5 years, with a median of -$4.1 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 15235.24% — and 2025, when it sank 99507.07%.
- Lantheus Holdings' Cash from Financing Activities stood at $317.8 million in 2022, then sank by 100.14% to -$450000.0 in 2023, then plunged by 22935.33% to -$103.7 million in 2024, then gained by 2.77% to -$100.8 million in 2025, then jumped by 88.47% to -$11.6 million in 2026.
- Business Quant data shows LNTH's Cash from Financing Activities at -$11.6 million in Q1 2026, -$100.8 million in Q4 2025, and -$99.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | 4.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.51 Mn |
| Jun 30, 2026 | 4.51 Mn |
| Mar 31, 2026 | -11.62 Mn |
| Mar 31, 2026 | -11.62 Mn |
| Dec 31, 2025 | -100.79 Mn |
| Dec 31, 2025 | -100.79 Mn |
| Sep 30, 2025 | -99.17 Mn |
| Sep 30, 2025 | -99.17 Mn |
| Jun 30, 2025 | -98.41 Mn |
| Jun 30, 2025 | -98.41 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Dec 31, 2024 | -103.66 Mn |
| Dec 31, 2024 | -103.66 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 99,000.00 |
| Mar 31, 2024 | -16.85 Mn |
| Mar 31, 2024 | -16.85 Mn |